Yixintang Pharmaceutical Group Third Quarter 2024 Earnings: EPS Misses Expectations

Yixintang Pharmaceutical Group (SZSE:002727) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥4.28b (up 3.6% from 3Q 2023).
• Net income: CN¥10.6m (down 94% from 3Q 2023).
• Profit margin: 0.2% (down from 4.4% in 3Q 2023).
• EPS: CN¥0.018 (down from CN¥0.30 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yixintang Pharmaceutical Group EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 93%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Consumer Retailing industry in China.

Performance of the Chinese Consumer Retailing industry.

The company's shares are down 1.0% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Yixintang Pharmaceutical Group you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.